en · de · es · fr · pt
dihexa-notes.peptides4800.com › Wiki › Dihexa Chemical Identity And Origin — Evidence Review

Dihexa Chemical Identity And Origin — Evidence Review

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-23 · Wiki

Everything below concerns Angiotensin IV analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Dihexa Chemical Identity and Origin

Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Overview and Research Status

Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.

Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Handling and Quality Verification

Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.

In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.

Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.

Related pages on this site

Handling, Storage, and Verification

Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.

Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.

Supporting material

== External links == Genome-based Peptide Fingerprint Scanning (GFS) Documentation Archived 27 September 2013 at the Wayback Machine Facebook link to "Genome-based Peptide Fingerprint Scanning" Explanation of MS/MS in relation to MASCOT

Homologous sequences are orthologous if they are inferred to be descended from the same ancestral sequence separated by a speciation event: when a species diverges into two separate species, the copies of a single gene in the two resulting species are said to be orthologous. Orthologs, or orthologous genes, are genes in different species that originated by vertical descent from a single gene of the last common ancestor. The term "ortholog" was coined in 1970 by the molecular evolutionist Walter Fitch. For instance, the plant Flu regulatory protein is present both in Arabidopsis (multicellular higher plant) and Chlamydomonas (single cell green algae). The Chlamydomonas version is more complex: it crosses the membrane twice rather than once, contains additional domains and undergoes alternative splicing. However, it can fully substitute the much simpler Arabidopsis protein, if transferred from algae to plant genome by means of genetic engineering. Significant sequence similarity and shared functional domains indicate that these two genes are orthologous genes, inherited from the shared ancestor. Orthology is strictly defined in terms of ancestry. Given that the exact ancestry of genes in different organisms is difficult to ascertain due to gene duplication and genome rearrangement events, the strongest evidence that two similar genes are orthologous is usually found by carrying out phylogenetic analysis of the gene lineage. Orthologs often, but not always, have the same function.

=== Protein tyrosine phosphatases === Protein Tyrosine Phosphatase (PTPs) are a group of enzymes that possess a catalytic domain with phosphotyrosine-specific phosphohydrolase activity. PTPs are capable of modifying the activity of receptor tyrosine kinases in both a positive and negative manner. PTPs can dephosphorylate the activated phosphorylated tyrosine residues on the RTKs which virtually leads to termination of the signal. Studies involving PTP1B, a widely known PTP involved in the regulation of the cell cycle and cytokine receptor signaling, has shown to dephosphorylate the epidermal growth factor receptor and the insulin receptor. Some PTPs, on the other hand, are cell surface receptors that play a positive role in cell signaling proliferation. Cd45, a cell surface glycoprotein, plays a critical role in antigen-stimulated dephosphorylation of specific phosphotyrosines that inhibit the Src pathway.

=== 1997–2016: Valve === In July 1997, Laidlaw joined the video game company Valve while they were developing their first game, the first-person shooter (FPS) Half-Life (1998). He was hired to work on another game, Prospero, but switched when it was cancelled and the Half-Life project expanded. Laidlaw said his contribution was to add "old storytelling tricks" to Valve's ambitious designs. Rather than dictate narrative elements, he worked with the team to improvise ideas and was inspired by their experiments. He contributed to the "visual grammar" of the level design and focused on "doing storytelling with the architecture ... The narrative had to be baked into the corridors." For Half-Life 2 (2004), Valve developed the characterization. Laidlaw created family relationships between the characters, saying it was a "basic dramatic unit everyone understands" that was rarely used in games. He also worked on Half-Life 2: Episode One (2006) and Half-Life 2: Episode Two (2007), plus several canceled Half-Life projects, including Half-Life 2: Episode Three and a virtual reality (VR) game set on a time-travelling ship. Laidlaw said he had intended Episode Three to end the Half-Life 2 story arc, at which point he would "step away from it and leave it to the next generation". In 2012, Laidlaw started a Twitter account to tell a story about the Half-Life 2 character Dr Breen. He described the story as "fan fiction", and wrote: "I personally cannot give the world a Half-Life game.

Sources: en.wikipedia.org

Supporting material

From November 3 – 6, 1898, the Negrense peoples rose in revolt against the local Spanish colonial government headed by politico-military governor Colonel Isidro de Castro. The Spaniards decided to surrender upon seeing armed troops marching in a pincer movement towards Bacolod. The revolutionaries, led by General Juan Araneta from Bago and General Aniceto Lacson from Talisay, bore fake arms consisting of rifles carved out of palm fronds and cannons of rolled bamboo mats painted black. By the afternoon of November 6, Col. de Castro signed the Act of Capitulation, thus ending centuries of Spanish colonial rule in Negros Occidental.

=== Biosensors === Graphene does not oxidize in air or in biological fluids, making it an attractive material for use as a biosensor. A graphene circuit can be configured as a field effect biosensor by applying biological capture molecules and blocking layers to the graphene, then controlling the voltage difference between the graphene and the liquid that includes the biological test sample. Of the various types of graphene sensors that can be made, biosensors were the first to be available for sale.

Polymeric drug delivery systems have overcome challenges due to their biodegradability, biocompatibility, and anti-toxicity. Materials such as collagen, chitosan, cellulose, and poly (lactic-co-glycolic acid) have been implemented extensively for drug delivery to organs such as eye, nose, kidneys, lungs, intestines, skin and brain. Future work is focused on reducing toxicity, improving biocompatibility, expanding assembly techniques Hydrogels have been considered as vehicles for drug delivery. They can also be made to mimic animal mucosal tissues to be used for testing mucoadhesive properties. They have been examined for use as reservoirs in topical drug delivery; particularly ionic drugs, delivered by iontophoresis. Biomimetic physical barrier that separates T cells from tumors, potentially allowing them to regain strength before resuming immunotherapy.

== Traditional medicine == Andean indigenous peoples use the tea in traditional medicine practices. Visitors to the city of Cuzco in Peru, and La Paz in Bolivia are greeted with the offering of coca leaf infusions (prepared in teapots with whole coca leaves) purportedly to help the newly arrived traveler overcome the malaise of high altitude sickness. Coca tea may be recommended for travelers in the Andes to prevent altitude sickness, although its actual effectiveness has never been systematically studied.

In 2015, 251 million tubes of toothpaste were sold in the United States. A single tube holds roughly 170 grams of toothpaste, so approximately 43 kilotonnes of toothpaste get washed into the water systems annually. Toothpaste contains silver nanoparticles, also known as nanosilver or AgNPs, among other compounds. Each tube of toothpaste contains approximately 91 mg of silver nanoparticles, with approximately 3.9 tonnes of silver nanoparticles entering the environment annually. Silver nanoparticles are not entirely cleared from the water during the wastewater treatment process, possibly leading to detrimental environmental effects.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

What is dihexa?

Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.

Network